Novo Nordisk Q3 Beat: Is a Comeback Finally Underway?

Novo Nordisk reported third-quarter results that initially seemed mixed: Ozempic sales fell 3% year over year to $4.5 billion, and Wegovy injections were flat at $3.1 billion. However, the company's oral Wegovy pill, launched in January, generated $810 million in revenue and surpassed 3 million prescriptions, with over 80% of users being new to GLP-1 treatments.

Total net sales rose 6% to $11.9 billion, beating analyst estimates. Net income dropped 16% to $2.5 billion due to non-cash impairment charges, but that didn't overshadow the top-line beat. More importantly, Novo raised its full-year 2026 guidance, now expecting flat revenue growth at the midpoint versus a previously implied 3% decline.

Investors cheered the results, sending the stock up 6% post-earnings. The positive surprise came from the strong uptake of oral Wegovy and the company's ability to offset declines in its legacy injectable products.

Looking ahead, Novo has several catalysts: international expansion of oral Wegovy (approved in Germany and the U.K.), a potential label expansion for metabolic dysfunction-associated steatohepatitis (MASH), the upcoming launch of CagriSema (which beat Wegovy in a head-to-head trial), and pipeline candidate zenagamtide. These factors could drive growth despite intensifying competition.

The company's comeback narrative is gaining traction after a rough two-year period. The Q3 report provides tangible evidence that Novo can innovate and adapt to changing patient preferences.

The strong performance of oral Wegovy is a game-changer. It addresses a key barrier for patients hesitant about injections, expanding the addressable market. With over 80% of users being new to GLP-1s, Novo is successfully bringing in fresh patients, which is crucial for long-term growth.

The raised guidance signals management's confidence in the business, even as Ozempic faces headwinds. The shift toward oral formulations and new products like CagriSema positions Novo to compete more effectively with Eli Lilly, its main rival in the weight-loss space.

CagriSema's superiority over Wegovy in clinical trials is particularly important. If approved, it could help Novo regain market share and sustain pricing power. Additionally, the pipeline candidate zenagamtide offers further upside potential.

For investors, the Q3 results suggest that Novo's worst days may be behind it. The stock has been under pressure due to slowing growth and competitive fears, but the beat-and-raise quarter could mark a turning point. The valuation may now look more attractive relative to future growth prospects.

However, risks remain: competition from Lilly's tirzepatide (Mounjaro/Zepbound) is fierce, and reimbursement challenges could limit uptake. But Novo's diversified approach and strong pipeline provide a buffer.